Filing Details

Accession Number:
0001628280-24-050094
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-05 16:46:45
Reporting Period:
2024-12-03
Accepted Time:
2024-12-05 16:46:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1157601 Madrigal Pharmaceuticals Inc. MDGL () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1014095 B Fred Craves C/O Bay City Capital Llc,
1000 4Th Street, Suite 500
San Rafael CA 94901
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-12-03 3,080 $315.21 11,520 No 4 S Indirect See Footnotes
Common Stock Disposition 2024-12-03 520 $315.90 11,000 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 360,076 Direct
Common Stock 11,210 Indirect See Footnote
Common Stock 1,261 Indirect See Footnotes
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.00 to $315.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  2. Represents shares held indirectly by Dr. Craves through the Craves Family Foundation.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.84 to $316.16, inclusive.
  4. Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
  5. These securities are held by Bay City Capital LLC ("BCC"). Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.